Aspirin in patients undergoing noncardiac surgery

P.J. Devereaux*, Marko Mrkobrada, Daniel I. Sessler, Kate Leslie, Pablo Alonso-Coello, Andrea Kurz, Juan Carlos Villar, Alben Sigamani, Bruce M. Biccard, Christian S. Meyhoff, Joel L. Parlow, Gordon Guyatt, Andrea Robinson, Amit X. Garg, Reitze N. Rodseth, Fernando Botto, Giovanna Lurati Buse, Denis Xavier, Matthew T.V. Chan, Maria TiboniDeborah Cook, Priya A. Kumar, Patrice Forget, G. Malaga, E. Fleischmann, M. Amir, J. Eikelboom, R. Mizera, D. Torres, C.Y. Wang, T. VanHelder, P. Paniagua, O. Berwanger, S. Srinathan, M. Graham, L. Pasin, Y. Le Manach, P Gao, J. Pogue, R. Whitlock, A. Lamy, C. Kearon, C. Baigent, C. Chow, S. Pettit, S. Chrolavicius, S. Yusuf, POISE-2 Investigators

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

674 Citations (Scopus)


There is substantial variability in the perioperative administration of aspirin in patients undergoing noncardiac surgery, both among patients who are already on an aspirin regimen and among those who are not.

Using a 2-by-2 factorial trial design, we randomly assigned 10,010 patients who were preparing to undergo noncardiac surgery and were at risk for vascular complications to receive aspirin or placebo and clonidine or placebo. The results of the aspirin trial are reported here. The patients were stratified according to whether they had not been taking aspirin before the study (initiation stratum, with 5628 patients) or they were already on an aspirin regimen (continuation stratum, with 4382 patients). Patients started taking aspirin (at a dose of 200 mg) or placebo just before surgery and continued it daily (at a dose of 100 mg) for 30 days in the initiation stratum and for 7 days in the continuation stratum, after which patients resumed their regular aspirin regimen. The primary outcome was a composite of death or nonfatal myocardial infarction at 30 days.

The primary outcome occurred in 351 of 4998 patients (7.0%) in the aspirin group and in 355 of 5012 patients (7.1%) in the placebo group (hazard ratio in the aspirin group, 0.99; 95% confidence interval [CI], 0.86 to 1.15; P=0.92). Major bleeding was more common in the aspirin group than in the placebo group (230 patients [4.6%] vs. 188 patients [3.8%]; hazard ratio, 1.23; 95% CI, 1.01, to 1.49; P=0.04). The primary and secondary outcome results were similar in the two aspirin strata.

Administration of aspirin before surgery and throughout the early postsurgical period had no significant effect on the rate of a composite of death or nonfatal myocardial infarction but increased the risk of major bleeding.
Original languageEnglish
Pages (from-to)1494-1503
Number of pages10
JournalThe New England Journal of Medicine
Early online date31 Mar 2014
Publication statusPublished - 17 Apr 2014

Bibliographical note

Funded by the Canadian Institutes of Health Research and others; POISE-2 number, NCT01082874.


Dive into the research topics of 'Aspirin in patients undergoing noncardiac surgery'. Together they form a unique fingerprint.

Cite this